117 related articles for article (PubMed ID: 26983446)
1. The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients.
Huzarski T; Byrski T; Gronwald J; Cybulski C; Oszurek O; Szwiec M; Gugała K; Stawicka M; Morawiec Z; Mierzwa T; Falco M; Janiszewska H; Kilar E; Marczyk E; Kozak-Klonowska B; Siołek M; Surdyka D; Wiśniowski R; Posmyk M; Domagała P; Sun P; Lubiński J; Narod SA;
Breast Cancer Res Treat; 2016 Apr; 156(2):371-8. PubMed ID: 26983446
[TBL] [Abstract][Full Text] [Related]
2. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.
Huzarski T; Byrski T; Gronwald J; Górski B; Domagala P; Cybulski C; Oszurek O; Szwiec M; Gugala K; Stawicka M; Morawiec Z; Mierzwa T; Janiszewska H; Kilar E; Marczyk E; Kozak-Klonowska B; Siolek M; Surdyka D; Wisniowski R; Posmyk M; Sun P; Lubinski J; Narod SA
J Clin Oncol; 2013 Sep; 31(26):3191-6. PubMed ID: 23940229
[TBL] [Abstract][Full Text] [Related]
3. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
4. Predictors of survival for breast cancer patients with a BRCA1 mutation.
Narod SA; Huzarski T; Gronwald J; Byrski T; Marczyk E; Cybulski C; Szwiec M; Wisniowski R; Birkenfeld B; Kilar E; Sibilski R; Sun P; Lubinski J
Breast Cancer Res Treat; 2018 Apr; 168(2):513-521. PubMed ID: 29247441
[TBL] [Abstract][Full Text] [Related]
5. Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
Narod SA; Metcalfe K; Lynch HT; Ghadirian P; Robidoux A; Tung N; Gaughan E; Kim-Sing C; Olopade OI; Foulkes WD; Robson M; Offit K; Jakubowska A; Byrski T; Huzarski T; Sun P; Lubinski J
Breast Cancer Res Treat; 2013 Feb; 138(1):273-9. PubMed ID: 23381743
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.
Kramer JL; Velazquez IA; Chen BE; Rosenberg PS; Struewing JP; Greene MH
J Clin Oncol; 2005 Dec; 23(34):8629-35. PubMed ID: 16314625
[TBL] [Abstract][Full Text] [Related]
7. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Domchek SM; Friebel TM; Neuhausen SL; Wagner T; Evans G; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson GE; Van't Veer L; Lynch HT; Olopade OI; Weber BL; Rebbeck TR
Lancet Oncol; 2006 Mar; 7(3):223-9. PubMed ID: 16510331
[TBL] [Abstract][Full Text] [Related]
8. Does oophorectomy reduce breast cancer mortality for BRCA mutation carriers after breast cancer?
Jacobson M; Narod SA
Expert Rev Anticancer Ther; 2018 Apr; 18(4):305-306. PubMed ID: 29431530
[No Abstract] [Full Text] [Related]
9. Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
Menkiszak J; Chudecka-Głaz A; Gronwald J; Cymbaluk-Płoska A; Celewicz A; Świniarska M; Wężowska M; Bedner R; Zielińska D; Tarnowska P; Jakubowicz J; Kojs Z
J Ovarian Res; 2016 Feb; 9():11. PubMed ID: 26928677
[TBL] [Abstract][Full Text] [Related]
10. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
[TBL] [Abstract][Full Text] [Related]
11. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
13. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
14. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.
Grann VR; Jacobson JS; Thomason D; Hershman D; Heitjan DF; Neugut AI
J Clin Oncol; 2002 May; 20(10):2520-9. PubMed ID: 12011131
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
[TBL] [Abstract][Full Text] [Related]
16. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
[TBL] [Abstract][Full Text] [Related]
19. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
20. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
